Radar · Industry landscape · the United States
Clinical Trials Technology Industry Landscape of the United States
1,116 Clinical Trials Technology companies in the United States, in one picture: who is hiring, who is raising money, who founded them, where they are based, what the news is about, which skills employers want and where the research is going. Updated September 2026.
1,116companies tracked
$11.1Bdisclosed funding
102hiring right now
170events · 24 months
2,388,337news articles · 12 months
Who leads Clinical Trials Technology in the United States
Shows 1,116 U.S. Clinical Trials Technology firms, highlighting the top hiring companies, the best‑funded firms, and the number currently hiring or with disclosed funding rounds.
open roles
Hiring now
ranked by live open roles
- 01
Alcanza Clinical Research11last posted Jun 2026
- 02
CenExel10last posted May 2026
- 03
Bexorg10last posted Jun 2026
- 04
Apex Focus Group9last posted May 2026
- 05
The START Center for Cancer Research9last posted Apr 2026
- 06
Care Access9last posted Apr 2026
- 07
Ascend Clinical9last posted May 2026
- 08
DelRicht Research9last posted Apr 2026
102 companies hiring · 5 posted in the last 30 days
disclosed funding
Most funded
disclosed totals, all rounds
- 01
Verily$2.8BSeries D · Mar 2026
- 02
Tempus$760MSeries G · Oct 2022
- 03
Title21 Health Solutions$656.3MSeries D · Jul 2022
- 04
Medable$528.4MSeries D · Oct 2021
- 05
Reify Health$477.9MSeries D · Apr 2022
- 06
Viz.ai$292MConventional Debt · Mar 2023
- 07
Evidation$259.5MGrant (prize money) · Mar 2025
- 08
4G Clinical$259.3MSeries C · Jun 2021
236 companies with disclosed rounds · $11.1B total
headcount
Largest teams
ranked by tracked headcount
- 01
Private Access1,060tracked employees
- 02
- 03
SCC Soft Computer543tracked employees
- 04
- 05
OneStudyTeam309tracked employees
- 06
Javara Research233tracked employees
- 07
Castor230tracked employees
- 08
Saama213tracked employees
72 companies with headcount data
share of events
Share of voice
share of all tracked sector news events, 24 months
- 01
Ledger Run7.8%17 tracked events
- 02
- 03
Ketryx6.8%15 tracked events
- 04
Autonomize5.9%13 tracked events
- 05
IQVIA5.9%13 tracked events
- 06
TriNetX5.0%11 tracked events
- 07
ClinData3.7%8 tracked events
- 08
Condor3.7%8 tracked events
219 tracked events across 65 companies
web reach
Most-used apps
the sites in this sector the web visits most
- 01
Signant Healthtop 500ksignanthealth.com
- 02
Suvodatop 500ksuvoda.com
- 03
Massive Biotop 500kmassivebio.com
- 04
Powertop 500kwithpower.com
- 05
AutoCruitmenttop 500kautocruitment.com
- 06
ClinicalConnectiontop 500kclinicalconnection.com
- 07
- 08
Qualiotop 1Mqualio.com
274 companies here run a site with a measured audience · 21 of them sit inside the web’s top million
articles
In the news
Prism news coverage, last 12 months
- 01
- 02
- 03
Labvantage21articles in the window
- 04
LabWare17articles in the window
- 05
- 06
Legit12articles in the window
- 07
Teranode12articles in the window
- 08
55 of these companies drew sector coverage in the window
Radar
See all 1,116 Clinical Trials Technology companies in the United States
Filter by funding, headcount, hiring and location, and export the list.
How the Clinical Trials Technology ecosystem in the United States grew, 2016–2025
Displays the annual count of new companies, with a peak of 66 founded in 2017 and 13 founded in 2025.
Companies founded / year
new Clinical Trials Technology companies in the United States
20162025
peak 66 in 2017
Companies raising / year
with a disclosed round that year
20162025
peak 42 in 2020
Disclosed funding / year
sum of disclosed rounds (USD)
20162025
peak $1.8B in 2021
Where Clinical Trials Technology companies in the United States are based
Hub 01
San Francisco
73 Clinical Trials Technology companies
29% of the Clinical Trials Technology companies across these hubs
73companies
$877.1Mdisclosed funding
7hiring now
Hub 02
New York City
45 Clinical Trials Technology companies
18% of the Clinical Trials Technology companies across these hubs
45companies
$649.1Mdisclosed funding
5hiring now
Hub 03
Boston
34 Clinical Trials Technology companies
13% of the Clinical Trials Technology companies across these hubs
34companies
$682Mdisclosed funding
4hiring now
Hub 04
Cambridge
24 Clinical Trials Technology companies
9% of the Clinical Trials Technology companies across these hubs
24companies
$253.6Mdisclosed funding
4hiring now
Hub 05
Austin
23 Clinical Trials Technology companies
9% of the Clinical Trials Technology companies across these hubs
23companies
$369.9Mdisclosed funding
4hiring now
generated artwork
Hub 06
San Diego
20 Clinical Trials Technology companies
8% of the Clinical Trials Technology companies across these hubs
20companies
$90.2Mdisclosed funding
4hiring now
Hub 07
Philadelphia
19 Clinical Trials Technology companies
7% of the Clinical Trials Technology companies across these hubs
19companies
$19.4Mdisclosed funding
1hiring now
Hub 08
Raleigh
18 Clinical Trials Technology companies
7% of the Clinical Trials Technology companies across these hubs
18companies
$27.5Mdisclosed funding
2hiring now
generated artwork
The Clinical Trials Technology market map of the United States: what these companies actually do
Breaks down product sub‑categories—healthtech, life sciences, enterprise tech, enterprise software, SaaS—and shows the most common revenue models, such as subscription and fee‑for‑service.
- Healthtech806 companies · $9.9B raised · 75 hiring
- Life Sciences806 companies · $9.9B raised · 75 hiring
- Enterprise Tech791 companies · $9.9B raised · 75 hiring
- Enterprise Software656 companies · $6.3B raised · 67 hiring
- SaaS397 companies · $4.9B raised · 49 hiring
- Healthtech SaaS397 companies · $4.9B raised · 49 hiring
- Clinical Data Repository200 companies · $350.4M raised · 15 hiring
- Consumer Digital67 companies · $310.3M raised · 3 hiring
- Native AI in Life Sciences24 companies · $1.4B raised · 2 hiring
- Native AI in Healthcare24 companies · $1.4B raised · 2 hiring
- Artificial Intelligence24 companies · $1.4B raised · 2 hiring
- Deep Tech15 companies · $285.8M raised · 1 hiring
Monetization
How Clinical Trials Technology companies make money
How many companies earn revenue each way. Plenty use more than one model, so the counts add up to more than the sector.
Subscription771
Fee-For-Service310
Commission on Transaction51
Advertising39
Physical Commerce25
E-Commerce - Product25
E-Commerce - Service21
Licensing6
Funding, M&A and the deals moving Clinical Trials Technology in the United States
Counts 170 corporate events over the past two years, including 74 key‑person moves, 37 mergers and acquisitions, and 30 funding rounds.
Leadership 74M&A 37Funding 30Contracts 6Assets 6Product 5Earnings 4Capital 2IPO 2Lawsuit 1
- M&ASignant Health has acquired Ametris, a wearable digital health systems manufacturer, in a tech M&A deal.2026-04-20
- FundingQuartzy, a vertically integrated procurement platform for the life sciences industry, announced it has secured $23 million in financing from Avenue Capital Group and BroadOak Capital Partners.2026-04-14
- FundingLast April, Verily received a $14.7 million grant from The Michael J. Fox Foundation for Parkinson’s Research.2026-03-24
- M&AFirst, he is simultaneously leading negotiations for multiple major mining assets, including ERG and Kazzinc—where, under the Glencore financing arrangement, he is expected to pursue the purchase of a 70% stake.2026-03-23
- FundingCondor Software has now raised a total of $29.5M in total equity funding and is backed by 645 Ventures, Bramalea Partners, Felicis, Insight Partners, Pamir Ventures, Prebys Ventures, and SNR.vc.2026-03-23
- M&AHomburger advised the shareholders of Swiss-based Clariness on the sale of 100% of their shares to SubjectWell.2026-01-28
- FundingAntidote, an AI-powered billing compliance platform for law firms, announced today it has raised $5 million in seed funding led by Lakestar, with participation from Concept Ventures, The LegalTech Fund, and several unnamed industry angels.2026-01-21
- M&ATitle21 Health Solutions acquired MyCellHub, a life sciences software provider, to enhance its digital health and laboratory management offerings.2026-01-07
- M&AIn an anticipated move, Dassault Systèmes, a French enterprise IT firm (its better-known aviation business is a separate company) will acquire Medidata Solutions, at a 17% premium over the stock price it had before rumors began circulating this spring.2026-01-01
- M&ABack in April, in an effort to support clinical trial sponsor’s trial designs with direct-to-patient and home healthcare provider capabilities, Myonex also acquired SaveWay Compounding Pharmacy.2026-01-01
Mergers and acquisitions
Deals from the last 24 months where a Clinical Trials Technology company in the United States was the buyer or the one bought, newest first. “Undisclosed” means the price was never published — not that the deal was worth nothing.
| Acquirer | Target | Deal value | Status | Date |
|---|---|---|---|---|
| Ametris | undisclosed | Announced | 2026-04-20 | |
| Shakhmurat Mutalip | undisclosed | Rumored | 2026-03-23 | |
| undisclosed | Announced | 2026-02-11 | ||
| undisclosed | Completed | 2026-01-12 | ||
| undisclosed | Announced | 2026-01-07 | ||
| $235M | Completed | 2026-01-01 |
Who is listing, hiring leaders, launching and winning work
Provides details on leadership changes, product launches and customer wins drawn from recent corporate events.
Leadership moves
27 tracked people moves · last 12 months
eClinical SolutionsVenu Mallarapu · Appointment → Chief Transformation and AI OfficerApr 2026
BrightInsightAndrew Schultz · Appointment → Executive Vice President of Sales and Commercial StrategyFeb 2026
CluePointsSinead Godkin · Appointment → Chief People OfficerJan 2026
RealTime eClinical SolutionsStephen Johnson · Retirement — was Chief Executive OfficerJan 2026
Product launches
tracked launches · last 12 months
Contract wins
6 customer wins · last 24 months
Quartzywon MP BiomedicalsFeb 2026
ERGwon stmicroelectronicsMar 2025
Sunquest Information Systemswon University of Pittsburgh Medical CenterFeb 2025
Phase Forwardwon novo nordiskFeb 2025
Earnings pulse
companies reporting results · last 24 months
4 companies reporting4 company-quarters tracked
Who is building Clinical Trials Technology in the United States
Profiles 592 founders and CEOs across 470 firms, noting frequent alma maters like Stanford (19) and MIT (11) and prior employers such as Microsoft (5).
Founders and chief executives12 of 592, from the best-funded companies on this page
Care Access, ex-Signal Vine, ex-Rock Health, The Johns Hopkins University School of Medicine
Ex-CEO EDUSURG · UCL MBBS, Stanford University MBA 2016
Ex-The Activity Exchange, IMRSV, OneRiot, Ask.com, University of Iowa PhD 2014
Healthcare Foundry, Co-Founder Overstory Health, Daymark Health, Tulea Health, Playground Pediatrics…
Paradigm, ex-Stealth Startup, ex-Icon, Western Washington University, 1991
Brightinsight, ex-The Boston Consulting, ex-Flex, University of Chicago Pritzker school of medicine, 2003
Ex-WCG, Bioclinica.
Ex-CEO n2y, FairWarning, Bullhorn, Peoplenet. Georgia Institute of Technology 1994, Emory University - Goizueta Business School MAB 2004
Ex-Pubget, Microsoft, Commonwealth Capital, The Yankee Group. Dartmouth College AB, UC Berkeley Haas School of Business MBA 2007
Where the founders studied
alma mater on record for 103 of 592 founders
Stanford University19
Massachusetts Institute of Technology11
University of Pennsylvania10
Harvard University9
Columbia University6
University of California (Berkeley)6
Cornell University5
Duke University4
Where they worked before
a previous employer on record for 19 of 592 founders
Microsoft5
Google3
Apple3
Cisco3
Intel2
Salesforce1
McKinsey1
Boston Consulting Group1
Founders flagged as repeat founders
of 510 founders with a profile on this page
5
carry a repeat-founder flag
- flagged as repeat founders5
- no repeat-founder flag505
Women and men among the founders
first names matched for 540 of 592 founders
16%
of matched founders are women
- women85
- men455
Inferred from first names, using 119 million people who state their own gender: a first name counts only where at least 20 of them share it and at least 90% of those share the same gender. The other 52 founders go in neither column.
Radar
Look up the people behind Clinical Trials Technology companies in the United States
Search founders, executives and operators by company, role and location.
Who funds Clinical Trials Technology in the United States
Summarizes 494 funding rounds since 2016 from 556 investors, with an average round size of $4.1 million.
| Investor · most active investors since 2016 | Rounds | Led | Latest |
|---|---|---|---|
| HHS | 35 | — | Dec 2025 |
| Y Combinator | 14 | 4 | Nov 2025 |
| Insight Partners | 12 | 9 | Mar 2026 |
| Merck Global Health Innovation Fund | 8 | 5 | Jul 2024 |
| Lux Capital | 8 | 2 | Dec 2025 |
| Europa | 8 | — | Jan 2024 |
| General Catalyst | 7 | 4 | Jan 2026 |
| Google Ventures | 7 | — | Dec 2025 |
| New Enterprise Associates | 6 | 4 | Oct 2021 |
| Boston Millennia Partners | 6 | 2 | Sep 2024 |
Stage mix · rounds since 2016
Seed & Angel152
Series A–B183
Series C+ / PE69
Grants, debt & other90
The typical round is $4.1M — half were bigger, half smaller.
The biggest Clinical Trials Technology funding rounds in the United States
Highlights the largest disclosed round—Title21 Health Solutions’ $656.3 million Series D—and lists ten other large recent rounds.
| Company | Round | Size | When | Backers |
|---|---|---|---|---|
| Series Dmega-round | $656.3M | Jul 2022 | ARCHIMED | |
| Series Dmega-round | $304M | Oct 2021 | Blackstone, Tiger Global Management, Sapphire Ventures +2 more | |
| Series Dmega-round | $300M | Mar 2026 | Series X Capital, Alphabet, UCHealth +1 more | |
| Series C | $230M | Jun 2021 | Goldman Sachs Investment Partners | |
| Series D | $220M | Apr 2022 | Altimeter Capital, Coatue, Dragoneer Investment Group +3 more | |
| Series C | $220M | Aug 2021 | Sierra Ventures, Coatue, Adams Street Partners +2 more | |
| Series A | $203M | Jan 2023 | Arch Venture Partners, General Catalyst, F-Prime Capital +5 more | |
| Series G | $200M | Dec 2020 | Google, Novo Holdings, Baillie Gifford +2 more | |
| Series F | $200M | May 2019 | New Enterprise Associates, Novo Holdings, Revolution +3 more | |
| Series E | $153M | Mar 2021 | McKesson, B Capital, OMERS |
Venture round sizes · 2023–2025
<$1M16
$1–10M38
$10–50M18
$50–250M5
>$250M0
77 venture rounds with a disclosed amount in the window.
Fresh cheques · last 6 months
SeedundisclosedApr 2026
Seed$1.2MFeb 2026
What the news says about Clinical Trials Technology in the United States
Counts 2,388,337 news articles in the last year, most often covering administrative, geopolitical and political topics.
News volume
Clinical Trials Technology coverage across United States · articles per quarter
2021Q22026Q2
peak 1,348,181 in 2025Q3 · 2,388,337 articles in the last 12 tracked months
Tone of coverage
share of articles by dominant sentiment (positive / neutral / negative)
202120232025
Positive-tone share moved 22% → 24%, negative 21% → 30% across 2021–2025.
What the coverage is about
The subjects that dominate Clinical Trials Technology news in United States. The arrow shows whether each one is being written about more or less than a year ago.
- Administrative and political subdivisions4,335,088▲+17%
- Geopolitical disputes and contested areas320,380▲+30%
- International and transnational geographic entities320,209▲+30%
- International political relations228,977→+1%
- Security and defense policies162,274▲+16%
- International relations and diplomacy104,833→-9%
- Trade policies and agreements83,078▼-27%
- Geographic naming conventions and etymology81,709▲+383%
- Human rights advocacy reports75,251▼-27%
- Political asylum and refugee policies60,563▼-31%
Most-covered companies · last 12 months
- 653
- 171
- 21
- 17
- 14
- 12
- 12
- 11
- 11
- 10
55 Clinical Trials Technology companies here were named in the news over this period.
Prism
Watch Clinical Trials Technology coverage in United States as it happens
Prism follows these subjects story by story — which companies are named, what is said about them and how the tone moves.
Momentum
The words getting louder — and quieter
Which terms are showing up in more stories than a year ago, and which are fading. The percentage is the change in how many articles mention them.
investment deal+141%oil price volatility+61%private equity+202%countries+100%share price+63%etf trading+116%stock surge+77%investment+250%commodity trading+87%export sanctions+161%
tariff negotiations-40%free trade deals-38%college playoffs-86%severe weather warning-45%economic slowdown-47%
The pressures the press keeps returning to
Three recurring angles in United States Clinical Trials Technology coverage, and whether each is getting more attention year on year (through 2025).
Regulatory Risk ▲ rising
1,887,582 articles touch this dimension · 44.8% critical tone
20212025
signals: territories, disputed islands, tariff negotiations
Funding Momentum ▲ rising
327,281 articles touch this dimension · 45.9% critical tone
20212025
signals: investment deal, inflation reports fx, currency intervention policies
Growth ▲ rising
487,335 articles touch this dimension · 39.3% critical tone
20212025
signals: earnings report, stock performance, quarterly results
Clinical Trials Technology jobs in the United States: who is hiring and what they ask for
Reports 3,713 job postings from 109 firms in the past year, with median advertised salary of $75 k and top skills including Python and driver’s‑license related qualifications.
3,713postings · last 12 months
4,920postings tracked overall
109employers advertising
$75kmedian advertised salary/yr (n=414)
Demand
The Skills Employers Ask For
What Clinical Trials Technology employers in the United States put in their job ads. The bar is how many postings ask for it; the arrow shows whether demand grew or shrank against the year before.
- ccc162▲
- driver\'s license53→
- motor vehicle physical damage appraisers license51▲
- python37▲
- email32▲
- excel27▲
- phlebotomy26▲
- electronic health records25▲
- web applications23▲
- microsoft applications23▲
What level are these roles?
Entry137
Intern16
Senior327
Lead245
Manager814
What they pay, by level
- Manager$111k/yr (n=79)
- Senior$115k/yr (n=42)
Most advertised titles
- 287
- 129
- 121
- 115
- 91
- 70
What Clinical Trials Technology research in the United States is working on
Indexes 13,110 U.S. academic papers, categorizing 1,583 on common problems, 522 on cautions, and 8,512 on opportunities.
How this field talks about itself
United States-affiliated Clinical Trials Technology papers (gold) against all published research (grey)
Breakthrough38.4% · 26.5%1.4×
Promising26.6% · 37.2%0.7×
Descriptive17.0% · 17.1%≈ par
Problem-identifying10.4% · 9.6%≈ par
Cautionary4.0% · 4.6%0.9×
Comparative2.0% · 3.9%0.5×
United States-affiliated Clinical Trials Technology literature runs 1.4× more “breakthrough” than science at large (38.4% vs 26.5% baseline).
How the work is done
Empirical38.6%
Methods-led34.1%
Reviews23.6%
Position pieces3.0%
Theoretical0.7%
How the research reads
92% positive · 5% neutral · 3% negative, across 13,110 papers.
The institutions doing the work · United States
- 424k
- 397k
- 309k
- 202k
- 184k
- 173k
ranked by how often their work is cited
Leading researchers · United States-affiliated work
Koichiro Tamura · Glen Stecher · Michael I. Love · Wolfgang Huber · Simon Anders · Sudhir Kumar · Douglas Hanahan · Robert A. Weinberg
The most-cited breakthroughs
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 97k cites
- MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets · 45k cites
- MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods · 40k cites
- MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms · 38k cites
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data · 29k cites
Common problems researchers identify1,536 papers · 7 recurring themes
Problems · theme 01
Biomarker and Disease Translation Gaps
280 papers · 18.2% of this block
▲ +46% share2022→2025 share of research on this subject
Researchers highlight challenges in moving metabolic biomarkers and disease diagnostics from discovery to clinical use.
Clinical trial · MEDLINE · Biomarker · Disease
“Evolving Paradigms in Chronic Limb-threatening Ischemia: A Systematic Review of Current and Emerging Diagnostic and Therapeutic Approaches”
280 of these papers raise it as a problem
Problems · theme 02
Cancer Immunotherapy Resistance Issues
269 papers · 17.5% of this block
▼ -4% share2022→2025 share of research on this subject
Papers flag obstacles in tumor microenvironment and checkpoint pathways that limit current cancer immunotherapies.
Cancer · Tumor microenvironment · Breast cancer · Immunotherapy
“Metabolic reprogramming and cancer progression”
269 of these papers raise it as a problem
Problems · theme 03
Genetic Variant Interpretation Difficulties
262 papers · 17.1% of this block
▼ -23% share2022→2025 share of research on this subject
Authors discuss inconsistencies and uncertainties in classifying and reporting gene variants for disease risk.
Gene · Genome · Gene expression · Genetic testing
“Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test result”
262 of these papers raise it as a problem
Problems · theme 04
Inflammation‑Driven Disease Mechanisms
262 papers · 17.1% of this block
▼ -13% share2022→2025 share of research on this subject
Works point to complex immune and metabolic pathways underlying neuro‑degenerative and cardiovascular disorders.
Disease · Inflammation · Pathogenesis · Immune system
“Parkinson’s disease: etiopathogenesis and treatment”
262 of these papers raise it as a problem
Problems · theme 05
Computational and Synthetic Biology Limits
184 papers · 12.0% of this block
▼ -6% share2022→2025 share of research on this subject
Studies note methodological gaps in metagenomics, epigenetics, and synthetic approaches for regenerative medicine.
Computational biology · Synthetic biology · Extracellular vesicles · Regenerative medicine
“Clinical metagenomics”
184 of these papers raise it as a problem
Problems · theme 06
Metabolic Disease and Obesity Links
173 papers · 11.3% of this block
▼ -15% share2022→2025 share of research on this subject
Literature emphasizes unresolved inflammatory mechanisms connecting obesity, insulin resistance, and diabetes treatment.
Diabetes mellitus · Disease · Obesity · Insulin resistance
“Inflammatory mechanisms linking obesity and metabolic disease”
173 of these papers raise it as a problem
Problems · theme 07
Microbiome Research Methodology Gaps
106 papers · 6.9% of this block
▲ +30% share2022→2025 share of research on this subject
Authors raise concerns about variability and translational relevance of gut microbiome studies.
Microbiome · Gut microbiome · Human microbiome · Gut flora
“Microbiota in health and diseases”
106 of these papers raise it as a problem
Cautions511 papers · 7 recurring themes
Cautions · theme 01
Target Validation Risks in Oncology
98 papers · 19.2% of this block
▼ -3% share2022→2025 share of research on this subject
Cautions focus on uncertain efficacy of emerging immune checkpoints and genomic biomarkers in cancer therapy.
Cancer · Breast cancer · Transcriptome · Tumor microenvironment
“[Strategic Combination Approaches in Cancer Immunotherapy].”
98 of these papers raise it as a problem
Cautions · theme 02
Unproven Therapeutic Claims
94 papers · 18.4% of this block
▲ +43% share2022→2025 share of research on this subject
Papers advise restraint when interpreting early‑stage clinical data for nutraceuticals and novel lipid‑lowering agents.
Drug · Drug discovery · Clinical trial · Disease
“The therapeutic potential of resveratrol: a review of clinical trials”
94 of these papers raise it as a problem
Cautions · theme 03
Epigenetic Marker Reliability Concerns
87 papers · 17.0% of this block
▼ -27% share2022→2025 share of research on this subject
Research warns about reproducibility and interpretation challenges for DNA methylation and protein‑structure biomarkers.
DNA methylation · Antibody · Protein structure · Epigenetics
“Characterizing the Conformational Dynamics of an Intrinsically Disordered Localization Sequence”
87 of these papers raise it as a problem
Cautions · theme 04
Genome Editing Transferability Issues
72 papers · 14.1% of this block
▼ -29% share2022→2025 share of research on this subject
Authors caution that plant‑focused genomic selection methods may not translate directly to human clinical contexts.
Gene · Genetic testing · Genome editing · Genome
“Genomic Selection for Crop Improvement”
72 of these papers raise it as a problem
Cautions · theme 05
Diabetes Treatment Outcome Variability
71 papers · 13.9% of this block
▼ -15% share2022→2025 share of research on this subject
Studies highlight inconsistent effects of SGLT2 inhibitors and insulin‑resistance metrics across patient subgroups.
Diabetes mellitus · Type 2 diabetes · Disease · MEDLINE
“Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayes”
71 of these papers raise it as a problem
Cautions · theme 06
Sequencing Bias and Benchmark Limits
59 papers · 11.5% of this block
▼ -3% share2022→2025 share of research on this subject
Works point out systematic biases in DNA sequencing pipelines and the need for more robust benchmarking.
DNA sequencing · Genome · Computational biology · Benchmark
“Characterizing and measuring bias in sequence data”
59 of these papers raise it as a problem
Cautions · theme 07
Long‑Term Microbiome Impact Uncertainty
30 papers · 5.9% of this block
▲ +31% share2022→2025 share of research on this subject
Research stresses limited understanding of lasting antibiotic effects on gut flora and related disease risks.
Microbiome · Gut flora · Gut microbiome · Metagenomics
“Long-term impacts of antibiotic exposure on the human intestinal microbiota”
30 of these papers raise it as a problem
Opportunities8,195 papers · 7 recurring themes
Opportunities · theme 01
Inflammation‑Targeted Therapeutic Development
1,108 papers · 18.5% of this block
▼ -13% share2022→2025 share of research on this subject
Opportunities focus on exploiting immune and metabolic pathways for new diabetes and cardiovascular treatments.
Disease · Inflammation · Diabetes mellitus · Immune system
“Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities”
Opportunities · theme 02
Genomic Insight for Drug Targeting
1,039 papers · 17.3% of this block
▼ -23% share2022→2025 share of research on this subject
Papers reveal how large‑scale gene association studies can pinpoint tissue‑specific disease drivers for drug discovery.
Genome · Gene · Genomics · Genome-wide association study
“Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types”
Opportunities · theme 03
Multi‑Omic Computational Platforms
951 papers · 15.8% of this block
▼ -6% share2022→2025 share of research on this subject
Research showcases advanced bioinformatics workflows enabling integrated protein, nucleic‑acid, and microbiome analyses.
Proteomics · Proteome · Computational biology · Workflow
“Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome \n”
Opportunities · theme 04
Novel Antimicrobial and Microfluidic Models
887 papers · 14.8% of this block
▲ +38% share2022→2025 share of research on this subject
Studies present emerging phytochemical agents and organ‑on‑chip systems for testing antimicrobial efficacy.
Antimicrobial · Epitope · Drug discovery · Antibiotics
“Bioactive Phytochemicals in Experimental Models of Multiple Sclerosis: Mechanisms, Efficacy, and Translational Potential”
Opportunities · theme 05
RNA‑Based Cancer Biomarkers
863 papers · 14.4% of this block
▼ -3% share2022→2025 share of research on this subject
Works highlight microRNA and stochastic modeling approaches to improve cancer diagnosis and therapy prediction.
Cancer · Breast cancer · Immunotherapy · Colorectal cancer
“MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer”
Opportunities · theme 06
CRISPR Gene‑Editing Therapeutics
667 papers · 11.1% of this block
▲ +11% share2022→2025 share of research on this subject
Papers discuss multiplexed CRISPR strategies and RNA‑editing tools for precise disease‑targeted interventions.
CRISPR · Genome editing · Cas9 · Gene
“Multiplex Genome Engineering Using CRISPR/Cas Systems”
Opportunities · theme 07
Spatial Transcriptomics for Cell Modeling
485 papers · 8.1% of this block
▼ -21% share2022→2025 share of research on this subject
Research emphasizes reconstructing cellular states from spatial gene‑expression data to guide disease modeling.
Transcriptome · Transcription factor · Gene · Gene expression
“Reconstructing biologically coherent cellular profiles from imaging-based spatial transcriptomics”
Which of these themes are growing fastest
Tracks how specific research themes have changed their share of global publications between 2022 and 2025.
Problems
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Biomarker and Disease Translation Gaps▲+46%
Microbiome Research Methodology Gaps▲+30%
Cancer Immunotherapy Resistance Issues▼-4%
Computational and Synthetic Biology Limits▼-6%
Inflammation‑Driven Disease Mechanisms▼-13%
Metabolic Disease and Obesity Links▼-15%
Genetic Variant Interpretation Difficulties▼-23%
Cautions
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Unproven Therapeutic Claims▲+43%
Long‑Term Microbiome Impact Uncertainty▲+31%
Target Validation Risks in Oncology▼-3%
Sequencing Bias and Benchmark Limits▼-3%
Diabetes Treatment Outcome Variability▼-15%
Epigenetic Marker Reliability Concerns▼-27%
Genome Editing Transferability Issues▼-29%
Opportunities
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Novel Antimicrobial and Microfluidic Models▲+38%
CRISPR Gene‑Editing Therapeutics▲+11%
RNA‑Based Cancer Biomarkers▼-3%
Multi‑Omic Computational Platforms▼-6%
Inflammation‑Targeted Therapeutic Development▼-13%
Spatial Transcriptomics for Cell Modeling▼-21%
Genomic Insight for Drug Targeting▼-23%
Prism
Go deeper on Clinical Trials Technology research and innovation
Research themes, patent activity and the companies commercialising them, in one place.
Keep going
Track Clinical Trials Technology in the United States beyond this page
Radar finds and filters the companies. Prism watches what is being said about them.
About this data: built from Fliar's company, founder, funding, hiring, jobs, news and research trackers, covering the United States. Counts are of companies we track, not of every company that exists. Updated September 2026.
Contact details
Reach this founder through Fliar Radar
Direct contact details for the people on this page are held in Fliar Radar, behind its own access controls.